HER2-targeted therapy influences CTC status in metastatic breast cancer

PURPOSE: As an independent, negative-prognostic biomarker for progression-free survival (PFS) and overall survival (OS), circulating tumor cells (CTCs) constitute a promising component for developing a liquid biopsy for patients with metastatic breast cancer (MBC). The effects of HER2-targeted thera...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Breast Cancer Res Treat
Autori principali: Deutsch, Thomas M., Riethdorf, Sabine, Fremd, Carlo, Feisst, Manuel, Nees, Juliane, Fischer, Chiara, Hartkopf, Andreas D., Pantel, Klaus, Trumpp, Andreas, Schütz, Florian, Schneeweiss, Andreas, Wallwiener, Markus
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer US 2020
Soggetti:
Clinical Trial
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7274999/
https://ncbi.nlm.nih.gov/pubmed/32436146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-020-05687-2
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi